The notion of CGRP playing a peripheral role in migraine is strongly supported by the effectiveness of systemically administered CGRP-targeting monoclonal antibodies, which exhibit poor permeability to the blood–brain barrier (BBB) [157]. Here, CALCA is linked to migraine disorder.